News
Gene editing technologies are changing the way we approach cell engineering. CRISPR-based gene editing can accurately modify genomic DNA to produce allogeneic and safer CAR T cells for cancer treatment.
Cancer is one of the leading causes of death in the United States, taking more than half a million lives each year according to the National…
News
Naturally developing cancers in animals can be used as models for human cancer treatment. The Biopharmaceutical Development Program successfully produced multiple antibodies for immune-oncology targets for clinical trials. More antibodies are in the discovery stage.
Dogs spontaneously develop cancers that resemble human malignancies. These…
News
Clinical trials are in progress for lentiviral-vector-based CD33 CAR T-cell treatments. The Biopharmaceutical Development Program manufactured the products for dose three, and dose four has just been initiated in 2023. The National Marrow Donor Program manages the trial. The Biopharmaceutical Development Program receives frozen apheresis on a set…
News
NCI-MATCH, one of the largest cancer precision medicine clinical trials to date, closed in 2023 and its follow-on studies will use a similar model to test combinations of treatments, evaluating a patient’s immune system prior to pairing the patient with immunotherapy against their cancer.
The Molecular Analysis for Therapy Choice (NCI-MATCH)…
News
Plants, marine invertebrates, and microbes have been a major source of novel drugs against cancer, viruses, and fungal diseases. New isolation methods are making it faster and easier to discover these natural products.
To encourage ongoing drug development from natural products, a collaboration of government and contractor scientists…
News
A growing body of evidence suggests that a single dose of vaccine against cancer-causing human papilloma virus (HPV) may protect as well as the standard two-or-more dose regimen. This would make it easier to protect more women, especially in low-income areas where vaccine access is scarce.
A study published recently in The Lancet Global Health…
News
A research collaboration has made early progress toward a potential vaccine for type 1 diabetes, a long-sought goal for an autoimmune disease that affects more than 1.5 million Americans.
The team, including Frederick National Laboratory computational scientist David Bell, previously discovered a new protein antibody in type 1 diabetes…
News
A research group including Frederick National Laboratory scientists has taken an early step toward a universal influenza vaccine that appears to protect against many strains, including the closely watched H5N1 bird flu. Human trials are under way.
Conventional seasonal flu vaccines target the rapidly mutating head of the hemagglutinin (HA)…
News
Maryland scientists came together earlier this month to discuss next-generation vaccine formulation and delivery, as the Biotech Connector speaker series returned to Frederick.
The Biotech Connector is a quarterly networking and speaker series, hosted by the Frederick National Laboratory for Cancer Research and Frederick County Chamber of…
News
Scientists at Frederick National Laboratory for Cancer Research and the National Cancer Institute have analyzed nearly two decades’ worth of data about biomedical nanotechnology studies, revealing patterns never seen before.
While that may seem exclusively like the domain of laboratory coats and computers, removed from the realm of public…
